BioCryst Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold Chief Medical OfficerGlobeNewsWire • 09/14/22
FDA Grants Orphan Drug Designation for BioCryst's ALK-2 Inhibitor, BCX9250, for the Treatment of Fibrodysplasia Ossificans ProgressivaGlobeNewsWire • 08/31/22
BioCryst Presents Data Demonstrating >99 Percent Suppression of Alternative Pathway Complement Activity with BCX9930 in C3G PatientsGlobeNewsWire • 08/26/22
U.S. Government Exercises Option to Purchase Additional RAPIVAB® (peramivir injection) from BioCryst for Pandemic Influenza PreparednessGlobeNewsWire • 08/25/22
BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q2 Results - Earnings Call TranscriptSeeking Alpha • 08/04/22
BioCryst Reports Second Quarter 2022 Financial Results and Upcoming Key MilestonesGlobeNewsWire • 08/04/22
BioCryst Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patients After Switching to ORLADEYO® (berotralstat)GlobeNewsWire • 07/01/22
BioCryst Announces ORLADEYO® (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022GlobeNewsWire • 06/22/22
Strength Seen in BioCryst (BCRX): Can Its 5.5% Jump Turn into More Strength?Zacks Investment Research • 06/20/22
BioCryst Selects Pint Pharma as Commercial Partner for ORLADEYO® (berotralstat) in Latin AmericaGlobeNewsWire • 06/09/22
BioCryst Announces Health Canada has Authorized ORLADEYO® (berotralstat), the Only Oral Treatment for the Prevention of Hereditary Angioedema AttacksGlobeNewsWire • 06/06/22
BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/05/22
BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/05/22